High rates of Pneumocystis carinii pneumonia in allogeneic blood and marrow transplant recipients receiving dapsone prophylaxis

Clinical Infectious Diseases

Volumn 29, Issue 6, 1999, Pages 1467-1471

  Souza, James P ^a,b   Boeckh, Michael ^a,d   Gooley, Ted A ^a   Flowers, Mary E D ^a   Crawford, Stephen W ^a,c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Idaho Cardiology Associates   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; DAPSONE;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; CHEMOPROPHYLAXIS; DRUG EFFICACY; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; INCIDENCE; INFECTION RISK; MALE; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RELAPSE;

ADULT; ANTI-INFECTIVE AGENTS; BONE MARROW TRANSPLANTATION; CLINICAL TRIALS; COHORT STUDIES; DAPSONE; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; PNEUMOCYSTIS; PNEUMONIA, PNEUMOCYSTIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 0033401315     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/313509     Document Type: Article

References (29)

1. 1. Meyers JD, Pifer LL, Sale GE, Thomas ED. The value or Pneumocystis carinii antibody and antigen detection for diagnosis of Pneumocystis carinii pneumonia after marrow transplantation. Am Rev Respir Dis 1979;120: 1283-7.
2. 2. Walter E, Chauncey T, Boeckh M, Hackman B, Kennedy M, Bowden R. PCP prophylaxis after marrow transplantation: efficacy of trimethoprim-sulfamethoxazole (trim-sulfa), role of trim-sulfa desensitization and iv pentamidine [abstract 32]. In: Program and abstracts of the 33d Interscience Conference on Antimicrobial Agents and Chemotherapy (New Orleans). Washington, DC: American Society for Microbiology, 1993:125.
3. 3. Tuan IZ, Dennison D, Weisdorf DJ. Pneumocystis carinii pneumonitis following bone marrow transplantation. Bone Marrow Transplant 1992;10: 267-72.
4. 4. Sepkowitz KA, Brown AE, Telzak EE, Gottlieb S, Armstrong D. Pneumocystis carinii pneumonia among patients without AIDS at a cancer hospital. JAMA 1992;267:832-7.
5. 5. Lyytikainen O, Ruutu T, Volin L, et al. Late onset Pneumocystis carinii pneumonia following allogeneic bone marrow transplantation. Bone Marrow Transplant 1996;17:1057-9.
6. 6. Winston DJ, Ho WG, Gale RP, Champlin RE. Prophylaxis of infection in bone marrow transplants. Eur J Cancer Clin Oncol 1988;24(Suppl): S15-23.
7. 7. Sepkowitz KA. Pneumocystis carinii pneumonia in patients without AIDS. Clin Infect Dis 1993;17(Suppl):S416-22.
8. 8. Walter EA, Bowden RA. Infection in the bone marrow transplant recipient. Infect Dis Clin North Am 1995;9:823-47.
9. 9. Bozette SA, Finkelstein DM, Spector SA, et al. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. N Engl J Med 1995;332:693-9.
10. 30. Link H, Vohringer HF, Wingen F, Bragas B, Schwardt A, Ehninger G. Pentamidine aerosol for prophylaxis of Pneumocystis carinii pneumonia after BMT. Bone Marrow Transplant 1993;11:403-6.
11. 11. Jorde UP, Horowitz HW, Wormser GP. Utility of dapsone for prophylaxis of Pneumocystis carinii pneumonia in trimethoprim-sulfamethoxazole-intolerant, HIV-infected individuals. AIDS 1993;7:355-9.
12. 12. Martin MA, Cox PH, Beck K, Styer CM, Beall GN. A comparison of the effectiveness of three regimens in the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus infected patients. Arch Intern Med 1992;152:523-8.
13. 13. Slavin MA, Hoy JF, Stewart K, Pettinger MB, Lucas CR, Kent SJ. Oral dapsone versus nebulized pentamidine for Pneumocystis carinii pneumonia prophylaxis: an open randomized prospective trial to assess efficacy and haematological toxicity. AIDS 1992;6:1169-74.
14. 14. Warnock AC, Rimland D. Comparison of trimethoprim-sulfamethoxazole, dapsone, and pentamidine in the prophylaxis of Pneumocystis carinii pneumonia. Pharmacotherapy 1996;16:1030-8.
15. 15. Blum RN, Miller LA, Gaggini LC, Cohn DL. Comparative trial of dapsone versus trimethoprim/sulfamethoxazole for primary prophylaxis of Pneumocystis carinii pneumonia. J Acquir Immune Defic Syndr 1992;5:341-7.
16. 16. Antinori A, Murri R, Ammassari A, et al. Aerosolized pentamidine, cotrimoxazole, and dapsone-pyrimethamine for primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis. AIDS 1995;9: 1343-50.
17. 17. Podzamczer D, Salaazar A, Jiminez J, et al. Intermittent trimethoprim-solfamethoxazole compared with dapsone-pyrimethamine for primary prevention of Pneumocystis carinii pneumonia and toxoplasmosis in patients infected with HIV. Ann Intern Med 1995;122:755-61.
18. 18. Podzamczer D, Santin M, Jiminez J, Casanova A, Bolao F, Gudiol F. Thrice-weekly cotrimoxazole is better than weekly dapsone-pyrimethamine for primary prevention of Pneumocystis carinii pneumonia in HIV-infected patients. AIDS 1993;7:501-6.
19. 19. Mallolas J, Zamora L, Gatell JM, et al. Primary prophylaxis for Pneumocystis carinii pneumonia: a randomized trial comparing cotrimoxazole, aerosolized pentamidine, and dapsone with pyrimethamine. AIDS 1993;7: 59-64.
20. 20. Hughes WT. Lise of dapsone in the prevention and treatment of Pneumocystis carinii pneumonia: a review. Clin Infect Dis 1998;27:191-204.
21. 21. Maltezou HC, Petropoulos D, Choroszy M, et al. Dapsone for Pneumocystis carinii prophylaxis in children undergoing bone marrow transplantation. Bone Marrow Transplant 1997;20:879-81.
22. 22. Purdy BH, Philips DM, Summers RW. Desensitization for sulfasalazine skin rash. Ann Intern Med 1984;100:512-4.
23. 23. Torres RA, Barr M, Thorn M, et al. Randomized trial of dapsone and aerosolized pentamidine for the prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis. Am J Med 1993;95:573-83.
24. 24. Pieters FAJM, Zuidema J. The absolute oral bioavailability of dapsone in dogs and humans. Int J Clin Pharmacol Ther Toxicol 1987;25:396-400.
25. 25. Atkinson K, Briggs JC, Britton K, et al. Oral administration of cyclosporine A for recipients of allogeneic marrow transplants: implications for clinical gut dysfunction. Br J Haematol 1984;56:223-31.
26. 26. Mandell GL, Sande MA. Antimicrobial agents: drugs used in the chemotherapy of tuberculosis and leprosy. In: Hardman JG, Limbird LF, Molinoff PB, Ruddon RW, Goodman Gilman A, eds. Goodman and Gilman's the pharmacological basis of therapeutics, 9th ed. New York: Pergamon Press, 1996:1155-74.
27. 27. Pieters FA, Zuidema J. The pharmacokinetics of dapsone after oral administration to healthy volunteers. Br J Clin Pharmacol 1986;22:491-4.
28. 28. Hughes W, Leoung G, Kramer F, et al. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. N Engl J Med 1993;328:1521-7.
29. 29. El-Sadr WM, Murphy RL, Yurik TM, et al. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. N Engl J Med 1998;339:1889-95.